Skip to main content

Advertisement

Table 4 Staging systems of patients with localized PG-DLBCL

From: Localized primary gastrointestinal diffuse large B cell lymphoma received a surgical approach: an analysis of prognostic factors and comparison of staging systems in 101 patients from a single institution

Staging system Stage N (%) 5-year RFS P value 5-year OS P value
Ann Arbor staging with Musshoff modification I (Ie1–Ie2) 62 (61) 86.8 ± 5.1 % 0.423 87.6 ± 5.3 % 0.428
II (IIe1–IIe2) 39 (52) 77.9 ± 7.4 % 76.1 ± 7.7 %
IPI Low 65 (64) 89.4 ± 4.5 % 0.006 90.9 ± 4.4 % 0.004
L–I 19 (19) 93.8 ± 6.1 % 93.8 ± 6.1 %
H–I 4 (4) 56.3 ± 14.8 % 55.6 ± 14.9 %
High 13 (13) 50.0 ± 2.5 % 50.0 ± 2.5 %
Lugano classification Early stage (I–II) 82 (81) 86.5 ± 4.5 % 0.039 85.4 ± 4.9 % 0.044
Late stage (IIE) 19 (19) 71.1 ± 11.0 % 76.0 ± 10.5 %
Paris staging system T 1 0 0.022 0.029
2 40 (40) 95.8 ± 4.1 % 94.7 ± 5.1 %
3 43 (42) 71.3 ± 8.1 % 73.7 ± 8.0 %
4 18 (18) 81.1 ± 9.9 % 80.4 ± 10.2 %
N 0 48 (48) 93.5 ± 4.5 % <0.001 92.2 ± 5.4 % <0.001
1 51 (50) 75.0 ± 6.9 % 77.2 ± 6.7 %
2 2 (2) 50.0 ± 35.4 % 50.0 ± 35.4 %
3 0
M 0 95 (94) 85.9 ± 4.2 % 0.018 86.2 ± 4.3 % 0.020
1 6 (6) 50.0 ± 20.4 % 50.0 ± 20.4 %
2 0
  1. Abbreviations: PG-DLBCL primary gastrointestinal diffuse large B cell lymphoma, RFS relapse-free survival, OS overall survival, IPI International Prognostic Index, L–I low–intermediate, H–I high–intermediate